{"id":"NCT02630992","sponsor":"Nader Shaikh","briefTitle":"Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media","officialTitle":"Reduced Clavulanate Formulation of Amoxicillin-Clavulanate in Children 6-23 Months With Acute Otitis Media","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2015-12","primaryCompletion":"2016-12","completion":"2017-07","firstPosted":"2015-12-15","resultsPosted":"2018-01-03","lastUpdate":"2018-01-03"},"enrollment":112,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"OTHER"},"conditions":["Acute Otitis Media"],"interventions":[{"type":"DRUG","name":"Amoxicillin-Clavulanate potassium","otherNames":["Augmentin"]}],"arms":[{"label":"amoxicillin-clavulanate potassium","type":"EXPERIMENTAL"}],"summary":"To evaluate the safety profile of amoxicillin-clavulanate potassium containing a reduced concentration of clavulanate potassium, 600 mg/21.5 mg/5 mL (a ratio of 28:1), administered at 90/3.2 mg/kg/day (formulation 1) or at 80/2.85 mg/kg/day (formulation 2) in two divided doses for 10 days. Investigators will focus on the proportion of subjects who develop protocol-defined diarrhea and proportion who develop diaper dermatitis that occasions the prescription of antifungal medication.","primaryOutcome":{"measure":"The Distribution of Participants Receiving Formulation 1 for Whom Protocol-Defined Diarrhea (PDD) Was Reported and Associated With Study Product","timeFrame":"Day 1 of administration of amoxicillin-clavulanate until day 12.","effectByArm":[{"arm":"Amoxicillin-clavulanate Potassium","deltaMin":10,"sd":null}],"pValues":[]},"eligibility":{"minAge":"6 Months","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":6},"locations":{"siteCount":1,"countries":["United States"]},"refs":{"pmids":["28438923"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":112},"commonTop":["Diaper dermatitis","Protocol defined diarrhea"]}}